Kisqali, blood tests and scans

nunthewizer

Kind wishes to all, doing research as a carer for my dear partner.
Not happy after progression on Arimadex, Ibrance after nearly 21 months in September.
Liver biopsy still ER+ HER2- but genomics tests revealed ESR1, ATM variants.
One week on Tomoxifen then Fulvestrant after genomics test came in.
Does every one know about genomics testing and in some cases can be done before progression to be proactive?
Not a panacea but targeted, precision oncology the future.

.Tumour markers not reliable in isolation, trend maybe, other bloods liver function etc, how you look and feel.
If you feel something is wrong get a second opinion.
Arimadex, Ibrance was standard of care, first line 2 years ago.
We’re you prescribed Fulvestrant, Kisqali first?
The recent San Antonio Symposium reported Ibrance no more effective than other CDK’s and when progression is finished but switch to  Kisqali yes.
PBS only allows one CDK4/6 so may as well be best efficacy/ side effects profile.
Not for everybody but medical CBD.
Resist other meds as far as possible.
Integrative, complementary.

Good news new drugs in development 
Orall SERD’s Orserdu $$ , Camizestrant etc and antibody drug conjugates, Dato-DXd etc
see San Antonio Breast Cancer Symposium, The evolving landscape of treatment after CDK4/6 inhibitors 

Cath62

Thanks for your comments @nunthewizer. Hope your partner is doing well.